Patent · US Active

Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt

US11279705B2 · kind B2 · utility

0Cited by

13References

3Claims

0Family size

Assignee

Ariad Pharmaceuticals, Inc. · US

Inventors

Christopher K. Murray · Lexington, US
Leonard W. Rozamus · Andover, US
John J. Chaber · Westford, US
Pradeep Sharma · Westford, US

Key dates

Filing date	May 22, 2020
Grant date	Mar 22, 2022
Priority date	—
Expiry date	May 22, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.